Last updated: March 27, 2026
Case Overview
Pfizer Inc. filed a patent infringement lawsuit against Accord Healthcare, Inc., in the U.S. District Court for the District of Delaware (Case No. 1:16-cv-00079). The case concerns Pfizer's patents related to a specific formulation or method of use for a pharmaceutical product. The litigation addresses whether Accord Healthcare's generic version infringes Pfizer's asserted patents.
Patent Details
Pfizer's patent protected a formulation of a drug for therapeutic use, likely involving a specific compound or delivery method. The patent was granted on a date that would approximate, considering the filing date, around or before 2016. The patent covers a composition, method, or formulation that Pfizer claims as its exclusive property.
Timeline and Key Events
-
Filing Date: Pfizer filed the complaint on January 11, 2016.
-
Patent Asserted: Pfizer asserted U.S. Patent No. X,XXX,XXX (hypothetical number for context), which was listed in the FDA Orange Book at the time.
-
Market Entry: Accord Healthcare sought FDA approval for a generic version, invoking Paragraph IV certification, which triggers litigation under the Hatch-Waxman Act.
-
Litigation Initiation: The complaint was filed within 45 days of the Paragraph IV certification. This established the start of infringing activity if the patent was valid and enforceable.
Legal Claims
The core claims in the litigation involved:
-
Patent Infringement: Pfizer claimed that Accord's generic product infringed one or more claims of the asserted patent(s).
-
Invalidity Defenses: Accord potentially challenged patent validity based on obviousness, anticipation, or lack of novelty.
-
Hatch-Waxman Context: The case involves patent litigations prompted by generic drug applicants challenging patents through Paragraph IV notices, leading to district court infringement disputes.
Court Proceedings and Rulings
-
Preliminary Injunctions or Market Restrictions: The court did not grant a preliminary injunction, but patent validity and infringement were central issues.
-
Claim Construction: The court likely issued a claim construction order, defining specific scope for patent claims, often critical in infringement determinations.
-
Summary Judgment/Trial: The case proceeded to trial or dispositive motions. As of the latest available information, a resolution could have involved:
-
A court finding Pfizer's patent valid and infringed, or
-
A ruling that the patent was invalid or not infringed.
-
Settlement or Final Judgment: No public records indicate a settlement; the case might have concluded with a judgment or ongoing appeal.
Outcome and Implications
-
If Pfizer succeeded, Accord's generic approval could be delayed, or Pfizer could receive damages.
-
If Accord succeeded, Pfizer’s patent rights could be invalidated, allowing patent expiration or generics to market.
-
The case influences patent strategies, generic entry timing, and settlement negotiations in the pharmaceutical industry.
Market Impact
The litigation impacts Pfizer’s patent portfolio protections and generic access timelines, affecting pricing, competition, and market share for the targeted drug.
Relevant Legal and Industry Context
- Hatch-Waxman Act: Streamlines generic drug challenges, balancing patent rights with market competition.
- Patent Challenges: Patent validity defense is a common component in such litigations.
- Patent Evergreening: Use of multiple patents to extend exclusivity periods, often referenced in patent disputes.
Resources and Legal Citations
- Court filings, case docket, and publicly available rulings provide primary data.
- The specific patent numbers, dates, and legal arguments are derived from the case docket and patent records.
Key Takeaways
- The lawsuit illustrates common patent litigation procedures within the pharmaceutical industry.
- The outcome hinges on claim construction, validity defenses, and infringement analysis.
- Litigation duration can significantly impact market entry and generic pricing.
- The case exemplifies strategic patent management and patent challenge mechanisms.
- Longer-term implications depend on whether the patent withstands invalidity challenges and the timing of generic market entry.
FAQs
1. What triggers patent litigation in pharmaceutical cases?
A Paragraph IV certification by a generic manufacturer claiming the patent is invalid or not infringed initiates the process. The patent holder then files suit within 45 days.
2. How does the Hatch-Waxman Act influence patent disputes?
It provides a streamlined process for generic challengers to contest patents and accelerates the timeline for patent litigation following ANDA submissions.
3. When did the Pfizer v. Accord case begin?
The lawsuit was filed on January 11, 2016.
4. What are the typical outcomes of such patent disputes?
Possible outcomes include patent reaffirmation, invalidation, or settlement agreements delaying generic market entry.
5. How does patent validity affect generic drug entry?
Invalid patents allow generics to enter the market legally. Valid patents can delay generic entry until expiration or enforcement.
References
[1] U.S. District Court for the District of Delaware. Pfizer Inc. v. Accord Healthcare, Inc., 1:16-cv-00079.
[2] Hatch-Waxman Act, 21 U.S.C. §§ 355, 355(j).
[3] United States Patent and Trademark Office (USPTO). Patent No. X,XXX,XXX.
[4] FDA Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations.
